



Institut
National du
Cancer

Towards a Comprehensive Cancer Centre
in Luxembourg:
Integration of Care, Research, and Education

Dr Nikolai GONCHARENKO, Director, INC Luxembourg



Introduction



Luxembourg: Actors in the field of cancer

Diagnostics & Treatment

- 4x general hospitals
- 1x National Radiotherapy Centre
- 1x National Pathology Centre

End of Life & Rehabilitation



National Health Fund





Luxembourg: Actors in the field of cancer

Prevention & Screening



LE GOUVERNEMENT
DU GRAND-DUCHÉ DE LUXEMBOURG
Ministère de la Santé
et de la Sécurité sociale

Foundations & Associations



FONDATIOUN
KRIIBSKRANK KANNER



Research & Education



LUXEMBOURG
INSTITUTE
OF HEALTH



Fonds National de la
Recherche Luxembourg



LE GOUVERNEMENT
DU GRAND-DUCHÉ DE LUXEMBOURG
Ministère de l'Enseignement supérieur
et de la Recherche




About the INC and PNC2



Founding of the INC

- **Founded in 2015**, as a non-profit association within the **1st National Cancer Plan** (2014-2018) of Luxembourg
- Mandated and funded by the **Ministry of Health and Social Security of Luxembourg**
- A **national entity overseeing and coordinating public and private actors** engaged in managing and providing healthcare services for cancer patients in Luxembourg (residents and cross-border workers)





Key objectives and activities


- Addressing the key questions linked to the **coordination of cancer care services**
- Development of **national guidelines** and **patient pathways**
- Set-up and development of **multidisciplinary tumour boards (TB)** for **rare and poor-prognosis cancers**
- Support the **implementation of personalised medicine**
- Advancing on the **equality of access** for all.





INC: Milestones & Achievements

- Available and being updated regularly (!) **national guidelines** and **care pathways for main cancer types** (colorectal, lung, breast, gynaecological, prostate, etc.)




INC: Milestones & Achievements



Institut
National du
Cancer


- Available and being updated regularly (!) **national guidelines** and **care pathways** for **main cancer types** (colorectal, lung, breast, gynaecological, prostate, etc.)





INC: Milestones & Achievements


- Available and being updated regularly (!) **national guidelines** and **care pathways for main cancer types** (colorectal, lung, breast, gynaecological, prostate, etc.)
- Operational **multidisciplinary tumour boards (TB)** for rare and poor-prognosis cancers, including molecular tumour boards (MTB)





INC: Milestones & Achievements


- Available and being updated regularly (!) **national guidelines** and **care pathways for main cancer types** (colorectal, lung, breast, gynaecological, prostate, etc.)
- Operational **multidisciplinary tumour boards (TB)** for **rare and poor-prognosis cancers**, including molecular tumour boards (MTB)
- Publication of a periodic **National Cancer Report**: first in 2020, next in 2026





INC: Milestones & Achievements

- Available and being updated regularly (!) **national guidelines** and **care pathways for main cancer types** (colorectal, lung, breast, gynaecological, prostate, etc.)
- Operational **multidisciplinary tumour boards (TB)** for rare and poor-prognosis cancers, including molecular tumour boards (MTB)
- Publication of a periodic **National Cancer Report**: first in 2020, next in 2026
- *Work in progress*: **National Cancer Collection (NCC)** for better data and biosample collection






INC: Milestones & Achievements

- Available and being updated regularly (!) **national guidelines** and **care pathways for main cancer types** (colorectal, lung, breast, gynaecological, prostate, etc.)
- Operational **multidisciplinary tumour boards (TB)** for **rare and poor-prognosis cancers**, including molecular tumour boards (MTB)
- Publication of a periodic **National Cancer Report**: first in 2020, next in 2026
- *Work in progress*: **National Cancer Collection (NCC)** for better data and biosample collection
- **Certification of cancer centres & networks** to improve the quality of care (e.g. lung cancer) → *collaborations DKG + JA CraNE.*

GROUPES DE TRAVAIL DU NCC :



INC: Milestones & Achievements


- Available and being updated regularly (!) **national guidelines** and **care pathways for main cancer types** (colorectal, lung, breast, gynaecological, prostate, etc.)
- Operational **multidisciplinary tumour boards (TB)** for **rare and poor-prognosis cancers**, including molecular tumour boards (MTB)
- Publication of a periodic **National Cancer Report**: first in 2020, next in 2026
- *Work in progress*: **National Cancer Collection (NCC)** for better data and biosample collection
- **Certification of cancer centres & networks** to improve the quality of care (e.g. lung cancer) → *collaborations DKG + JA CraNE*.

Public utility status
(as of 27th July 2024)



Institut
National du
Cancer

GROUPES DE TRAVAIL DU NCC :



EUROPEAN
CANCER
CENTRES

DKG
GERMAN CANCER SOCIETY

2nd National Cancer Plan 2020-2026 (PNC2)



Institut
National du
Cancer



LE GOUVERNEMENT
DU GRAND-DUCHÉ DE LUXEMBOURG
Ministère de la Santé
et de la Sécurité sociale



Plan
National
Cancer

- **Launched in 2020** by the **Directorate of Health**, the administrative arm of the Ministry of Health and Social Security of Luxembourg
- **Paused in 2021/2** due to the covid-19 pandemic
- **Extended: 2024 → 2026**



Role of the INC in the 2nd National Cancer Plan (PNC2)



Institut
National du
Cancer



LE GOUVERNEMENT
DU GRAND-DUCHÉ DE LUXEMBOURG
Ministère de la Santé
et de la Sécurité sociale

Direction de la santé

Axe 1

**Gouvernance, Ressources,
Monitoring et Reporting**, pour
une meilleure organisation des
soins en cancérologie
au Luxembourg

Axe 2

eMédecine, pour une
modernisation du pays dans
le cadre de l'informatisation
des données co
et échangées

Axe 3

**Droits, Information et Formation
des patients**, pour une
progression des droits actuels
des patients grâce à l'engagement
actif de ceux-ci dans les instances
décisionnelles

Axe 4

**Prévention, Dépistage et
Épidémiologie**, pour le
développement de mesures
préventives au niveau du cancer,
en synergie avec d'autres
plans nationaux

Axe 5

Diagnostic, pour
l'optimisation du diagnostic,
la personnalisation des
traitements et le suivi des
patients concernés

Axe 6

**Traitement, Soins
pluridisciplinaires, Soins
de support et le Soutien aux
patients**, pour un accès aux
soins et aux traitements
de qualité

Axe 8

**Recherche clinique et
translationnelle**, pour le
développement de la recherche
clinique et translationnelle
dans le pays


Axe 7

**Oncopédiatrie et
Oncogériatrie**, pour
l'amélioration de la qualité et
du suivi des patients aux âges
extrêmes de la vie

Central role in each
one of the axes:
mentioned 35 times



Activities of the INC



2nd National Cancer Plan 2020-2026 (PNC2)



Institut
National du
Cancer



Plan
National
Cancer

European projects : alignment with our National Cancer Plan

Obj 1.2 —

Soutien des établissements hospitaliers et des prestataires extra-hospitaliers dans la création de réseaux de compétence en oncologie et autres filières de collaboration.

Obj 1.3 —

Amélioration de la coordination/collaboration entre les différents organismes et services d'abord, dans le pays, puis à l'étranger.

Obj 1.8 —

Monitoring de la qualité de la prise en charge en cancérologie.





Institut
National du
Cancer

Joint Action EUNetCCC (CraNE-2)

Establishing a European Network of Comprehensive Cancer Centers

Establishing a European Network of CCC

What is EUnetCCC?

- A pan-European network of Comprehensive Cancer Centres (CCCs) aimed at harmonising cancer care
- Focus on collaboration, high-quality clinical care, research, and education across the EU
- Continuation of the JA CraNE (“Preparatory activities on the creation of national Comprehensive Cancer Centres and the EU Networking”)



Primary Objective

- Ensure access to high-quality cancer care, research, and innovative treatments for 90% of EU citizens.

Establishing a European Network of CCC

What is EUnetCCC?

- A pan-European network of Comprehensive Cancer harmonising cancer care
- Focus on collaboration, high-quality clinical care, research
- Continuation of the JA CraNE (“Preparatory activities for the European Network of Comprehensive Cancer Centres and the EU Network of Comprehensive Cancer Centres”)

Primary Objective

- Ensure access to high-quality cancer care, research, and prevention for 90% of EU citizens.



CraNE European Network of Comprehensive Cancer Centres

D7.2 Set of criteria and standards and their application in a certification process for EU Comprehensive Cancer Centres

Author(s):	Thomas Dubois , Margaux Legall, Chloe Jegou (Institut National du Cancer), Per Magnus Mæhle and Ingrid Jenny Guldvik (Oslo University Hospital)
Contributor(s):	WP7 partners
Work Package:	WP7
Date:	31.07. 2024



Co-funded by the
European Union

CraNE Joint Action is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them. The authors are not responsible for any further and future use of the report by third parties and third-party translations.

Page 1 of 231

Establishing a European Network of CCC



What is EUnetCCC?

- A pan-European network of Comprehensive Cancer Centres harmonising cancer care
- Focus on collaboration, high-quality research
- Continuation of the JA CraNE ("Pan-European Network of Comprehensive Cancer Centres")

Primary Objective

- Ensure access to high-quality cancer care for 90% of EU citizens.



3.1.1 EUCCCs conduct bench-to-bedside research and opposite

Clarification of the criterion: For a comprehensive understanding of cancer development, progression, and the creation of effective diagnostics and therapies, EUCCCs integrate the pillars of basic, translational, and clinical research. This integration accelerates the implementation of findings into clinical routine practice but also the opposite way by facilitating the journey of questions from the clinic to the agenda of translational research. To uphold their status, EUCCCs actively engage in all three research domains, with an emphasis on leading roles in translational and clinical research projects.

Standards:	Evidence:
3.1.1.1 At least one organizational entity that makes up an EUCCC has in-house activity in translational research or is integrated in a network conducting translational research. (CORE)	
3.1.1.2 All units providing cancer care in the EUCCC is integrated in a network allowing clinical research activities. (CORE)	
3.1.1.3 The centre is part of a network that processes facilitating mutual interactions between translational research and clinical practice (transforming findings from translational research to clinical practise and bringing questions raised in clinical practise to the table of translational research).	
3.1.1.4 The EUCCC has either activity or have a formally organised collaboration with an institution conducting: <ul style="list-style-type: none">• Basic research• Epidemiological research• Health care research	

and
process
res

nal du Cancer), Per
cal))



Key data, budget and resources

Involvement

- **EU:** 27 Members States + 4 Associated Countries
- **Luxembourg:** INC + all national actors (*next slide*)

Duration

- 4 years

Key roles

- **EU:** France (INCa) + Belgium, Slovenia and Norway
- **Luxembourg:**
 - Project management by the INC
 - Expertise of the participating institutions

Budget (total LU)

- **EU:** €112 mln; **LU:** 285 person-months / €3,9 mln
- **Funding modalities:** 80% EC: 20% national institutions → **EU:** €134 mln ; **LU:** €4,6 mln



Engagement of all national actors



Institut
National du
Cancer



LE GOUVERNEMENT
DU GRAND-DUCHÉ DE LUXEMBOURG
Ministère de la Santé
et de la Sécurité sociale


Direction de la santé

- ✓ INC (*beneficiary*)
- ✓ 4 hospitals – care (*affiliated entities*)
- ✓ CFB – care (*affiliated entity*)
- ✓ Rehabilitation Centre “Colpach” – care (*affiliated entity*)
- ✓ LNS – diagnostics (*affiliated entity*)
- ✓ LIH – research (*affiliated entity*)
- ✓ Uni.lu – education (*affiliated entity*)
- ✓ DiSa – prevention & screening (*affiliated entity*)



Establishing a European Network of CCC


➤ *What does this mean practically?*



EUNetCCC: project structure



Institut
National du
Cancer





Phased approach to Luxembourg pilot

Phase I: Preparatory

- Evaluating Luxembourg's current cancer framework (PNC2)
- Gap analysis using the CCC Maturity Model
- Aligning national resources with the CCC model

Phase II: Set-Up

- Setting up a CCC and forming comprehensive cancer care networks
- Creating national and cross-border collaborations

Phase III: EU Networking Phase

- Luxembourg's integration into the European CCC network
- Formalising connections with neighbouring countries (BE, DE, FR).

Phased approach to Luxembourg pilot

Phase I: Preparatory

- Evaluating Luxembourg's current cancer framework (PNC2)



- Setting up a CCC and forming comprehensive cancer care networks
- Creating national and cross-border collaborations

Phase III: EU Networking Phase


- Luxembourg's integration into the European CCC network
- Formalising connections with neighbouring countries (BE, DE, FR).

Luxembourg: a national CCC



Institut
National du
Cancer

Luxembourg Comprehensive Cancer Infrastructure



LIH: Luxembourg Institute of Health
LISER: Luxembourg Institute of Socio-Economic Research
RNC: National Cancer Registry
DiSa: Directorate of Health

CHL: Centre Hospitalier de Luxembourg
HRS: Hôpitaux Robert Schuman
CHEM: Centre Hospitalier Emile Mayrisch
CHdN: Centre Hospitalier du Nord





Added value for Luxembourg



Key benefits

Enhanced cancer care

- Access to the latest diagnostics and treatments
- Standardised quality of care
- Access to innovative clinical trials.

Integration into EU cancer networks

- Luxembourg's healthcare system will interconnect with the broader EU CCC network
- Improved cross-border collaboration, particularly with neighbouring countries (France, Germany, Belgium).

Advancing research

Research collaboration

- Collaboration on cutting-edge cancer research with top institutions in the EU
- Facilitated knowledge exchange and shared access to research findings.

Focus on translational research

- Strengthening links between national research institutions (LIH, Uni.lu) and clinical care
- Development of personalised therapies and precision oncology.



Strengthening cancer education and training

Expertise to support education activities

- Further development of academic programmes (oncology, nursing...)
- Participation in the EU-wide educational forums and workshops.

Cross-border educational initiatives

- Access to training programs for healthcare professionals
- Highly specialised training available cross-border, e.g. multidisciplinary tumour boards.



Cross-border collaborations

Key focus areas

- **Multidisciplinary Tumour Boards (MTB)**
formalising and extending existing collaborations
- **Formalising pathways**
for rare and poor-prognosis cancers, and complex situations
inc. clinical trials
- **Cross-border links (“partnerships”)**
via CCCNs networks with CCC in the neighbouring countries





Conclusions

A transformative initiative to enhance cancer care,
research, and education

synergistic with other national and EU projects

- Improved patient outcomes through shared knowledge, resources, and expertise
- Luxembourg becoming an active member of Europe's Comprehensive Cancer Care network.





Thank you for your attention!



INC

1b rue Thomas Edison

L-1445 Strassen

www.inc.lu

